Biodegradable magnesium (Mg) alloys are expected to be promising materials for
cardiovascular stents (CVS), which can avoid the long-term clinical problems of current CVS …

Platelets participate centrally in atherothrombosis, resulting in vessel occlusion and
ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further …

Detection of in vivo biodegradation is critical for development of next-generation medical
devices such as bioresorbable stents or scaffolds (BRSs). In particular, it is urgent to …

The existing biodegradable magnesium alloy stent (BMgS) structure is prone to problems,
such as insufficient support capacity and early fracture at areas of concentrated stress …

1University of Pisa and University Cardiology Division, Pisa University Hospital, Pisa, Italy;
and 2Fondazione VillaSerena per la Ricerca, Città Sant'Angelo, Pescara, Italy How to best …

Cardiovascular disease, including ischemic heart disease, is the leading cause of death
worldwide, and percutaneous coronary interventions (PCIs) have been demonstrated to …

Importance Stenting small-vessel lesions has an increased adverse cardiovascular event
risk. Very thin-strut or ultrathin-strut drug-eluting stents might reduce this risk, but data are …

Thinner biodegradable magnesium alloy stents (BMgSs) afford faster endothelialisation to
delay degradation and better clinical performance. However, compared with traditional non …

Background: Data regarding the use of percutaneous coronary intervention with drug-eluting
balloons (DEB) versus thin-strut drug-eluting stents (thin-DES) for treating DES in-stent …

Metallic drug-eluting stents have led to significant improvements in clinical outcomes but are
inherently limited by their caging of the vessel wall. Fully bioresorbable scaffolds (BRS) have …